SCHEMBL634442

SCHEMBL634442

CCOC(=O)Cn1cc(C(=O)O)c2nc3c(C)cccc3cc2c1=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.43
POLB P06746 1/20 0.43
TDP1 Q9NUW8 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 1/20 0.41
LMNA P02545 1/20 0.41
ALDH1A1 P00352 3/20 0.41
MAPT P10636 3/20 0.41
HTT P42858 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
PRNP P04156 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
ALOX15 P16050 1/20 0.40
CYP3A4 P08684 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
KDM4E B2RXH2 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL635605 0.88 TNF (0.52) TNF
SCHEMBL635320 0.87 KMT2A (0.44) L3MBTL1MEN1KMT2ATSHRLMNA
SCHEMBL634157 0.84 RAD52 (0.44) LMNAALDH1A1HTTHSD17B10CYP1A2
SCHEMBL634900 0.83 KDM4E (0.45) MEN1KMT2AALDH1A1MAPTHTT
SCHEMBL634012 0.83 KDM4E (0.40) L3MBTL1MEN1KMT2ALMNAALDH1A1
SCHEMBL632020 0.81 CNR2 (0.39) L3MBTL1POLBMEN1KMT2AALDH1A1
SCHEMBL635404 0.81 PTGDR2 (0.39) L3MBTL1MEN1KMT2ALMNAALDH1A1
SCHEMBL635677 0.81 KDM4E (0.36) L3MBTL1MEN1KMT2ALMNAALDH1A1
SCHEMBL634087 0.79 KDM4E (0.41) L3MBTL1POLBMEN1KMT2ALMNA
SCHEMBL30122318 0.79 KDM4E (0.41) L3MBTL1POLBMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090156630-A1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES BAGULEY BRUCE CHARLES 2009-06-18 US claimed
EP-1507778-B1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES UNIV TROBE (AU) 2012-02-22 EP disclosed
US-20090156630-A1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES BAGULEY BRUCE CHARLES 2009-06-18 US disclosed
US-7504507-B2 Anti-tumour polycyclic carboxamides AUCKLAND UNISERVICES LIMITED (NZ) 2009-03-17 US disclosed
US-20050245561-A1 Anti-tumour polycyclic carboxamides AUCKLAND UNISERVICES LIMITED (NZ) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156630-A1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES MKI67, MCL1, CCNI L3MBTL1 4102/4885POLB 258/4885TDP1 1786/4885
US-20050245561-A1 Anti-tumour polycyclic carboxamides MKI67, MCL1, CCNI L3MBTL1 3858/4885POLB 200/4885TDP1 1893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.